HomeCompareCCRRF vs MRK

CCRRF vs MRK: Dividend Comparison 2026

CCRRF yields 100000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CCRRF wins by $4.832206901976048e+26M in total portfolio value
10 years
CCRRF
CCRRF
● Live price
100000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.832206901976048e+26M
Annual income
$482,271,988,201,431,700,000,000,000,000,000.00
Full CCRRF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CCRRF vs MRK

📍 CCRRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCCRRFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CCRRF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CCRRF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CCRRF
Annual income on $10K today (after 15% tax)
$8,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$409,931,189,971,216,900,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CCRRF beats the other by $409,931,189,971,216,900,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CCRRF + MRK for your $10,000?

CCRRF: 50%MRK: 50%
100% MRK50/50100% CCRRF
Portfolio after 10yr
$2.416103450988024e+26M
Annual income
$241,135,994,100,715,840,000,000,000,000,000.00/yr
Blended yield
99.80%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CCRRF
No analyst data
Altman Z
-2.6
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CCRRF buys
0
MRK buys
0
No recent congressional trades found for CCRRF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCCRRFMRK
Forward yield100000.00%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.832206901976048e+26M$56.8K
Annual income after 10y$482,271,988,201,431,700,000,000,000,000,000.00$9,798.13
Total dividends collected$4.8315851896727036e+26M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CCRRF vs MRK ($10,000, DRIP)

YearCCRRF PortfolioCCRRF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,010,700$10,000,000.00$11,206$366.19+$10.00MCCRRF
2$9,366,505,842$9,355,794,392.52$12,650$502.35+$9366.49MCCRRF
3$8,191,091,111,834$8,181,068,950,583.78$14,407$694.19+$8191091.10MCCRRF
4$6,695,134,751,499,451$6,686,370,284,009,789.00$16,585$967.82+$6695134751.48MCCRRF
5$5,114,850,040,116,031,000$5,107,686,245,931,928,000.00$19,342$1,363.89+$5114850040116.01MCCRRF
6$3,652,290,278,277,141,000,000$3,646,817,388,734,216,400,000.00$22,913$1,947.19+$3652290278277141.00MCCRRF
7$2,437,583,176,648,375,000,000,000$2,433,675,226,050,619,000,000,000.00$27,662$2,823.89+$2437583176648375296.00MCCRRF
8$1,520,612,508,079,010,700,000,000,000$1,518,004,294,079,997,000,000,000,000.00$34,159$4,173.35+$1.5206125080790106e+21MCCRRF
9$886,637,379,601,106,600,000,000,000,000$885,010,324,217,461,900,000,000,000,000.00$43,337$6,308.80+$8.866373796011065e+23MCCRRF
10$483,220,690,197,604,800,000,000,000,000,000$482,271,988,201,431,700,000,000,000,000,000.00$56,776$9,798.13+$4.832206901976048e+26MCCRRF

CCRRF vs MRK: Complete Analysis 2026

CCRRFStock

Green River Gold Corp. engages in the acquisition, exploration, and development of mineral properties in Canada. It operates in two divisions, Retail and Mining. The company primarily explores for alluvial gold properties. Its principal project is the 100% owned Fontaine Gold Project that covers approximately 8,920 hectares located in British Columbia. The company also holds 100% interests in the Little Swift Gold and Sovereign Gold projects; the Kymar Silver project located in British Columbia; and the Quesnel Nickel/Cobalt Project consists of 8 contiguous mineral claims comprising 2,219.34 hectares located in British Columbia. In addition, it owns and operates retail stores that sells mining equipment. The company was formerly known as Greywacke Exploration Limited and changed its name to Green River Gold Corp. in August 2017. Green River Gold Corp. was incorporated in 2006 and is headquartered in Edmonton, Canada.

Full CCRRF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CCRRF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CCRRF vs SCHDCCRRF vs JEPICCRRF vs OCCRRF vs KOCCRRF vs MAINCCRRF vs JNJCCRRF vs ABBVCCRRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.